The results of our study confirm a case report of a CTEPH patient with a pathogenic variant in BMPR2 [17] and a larger study with 49 CTEPH patients which identified BMPR2 pathogenic variants in about 10% of patients [17,18]. This evidence concerns the gene BMPR2 and chronic thromboembolic pulmonary hypertension.